{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:43:32Z","timestamp":1793108612464,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K08517"],"award-info":[{"award-number":["20K08517"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ijid.2022.09.015","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:01:19Z","timestamp":1663286479000},"page":"124-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Extended-spectrum antibiotics for community-acquired pneumonia with a low risk for drug-resistant pathogens"],"prefix":"10.1016","volume":"124","author":[{"given":"Hironori","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0207-9483","authenticated-orcid":false,"given":"Yuichiro","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7364-5115","authenticated-orcid":false,"given":"Hideo","family":"Saka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2983-1919","authenticated-orcid":false,"given":"Shigeyuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-4631","authenticated-orcid":false,"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.09.015_bib0001","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cir840","article-title":"Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia","volume":"54","author":"Aliberti","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.015_bib0002","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(21)00630-9","article-title":"Community-acquired pneumonia","volume":"398","author":"Aliberti","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2022.09.015_bib0003","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0004","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1183\/09031936.00141110","article-title":"Guideline-concordant therapy and outcomes in healthcare-associated pneumonia","volume":"38","author":"Attridge","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2022.09.015_bib0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12879-015-0925-9","article-title":"Impact of Clostridium difficile infection among pneumonia and urinary tract infection hospitalizations: an analysis of the Nationwide inpatient sample","volume":"15","author":"Becerra","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.015_bib0006","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cmi.2020.03.019","article-title":"Acute kidney injury following the concurrent administration of antipseudomonal beta-lactams and vancomycin: a network meta-analysis","volume":"26","author":"Bellos","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.09.015_bib0007","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/CCM.0000000000002245","article-title":"Impact of acute kidney injury in patients hospitalized with pneumonia","volume":"45","author":"Chawla","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0008","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ijid.2022.09.015_bib0009","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1164\/rccm.200602-177OC","article-title":"Development and validation of a clinical prediction rule for severe community-acquired pneumonia","volume":"174","author":"Espa\u00f1a","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0010","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cmi.2019.02.022","article-title":"Healthcare-associated pneumonia: is there any reason to continue to utilize this label in 2019?","volume":"25","author":"Ewig","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.09.015_bib0011","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"336","author":"Fine","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0012","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/archinte.159.21.2562","article-title":"Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia","volume":"159","author":"Gleason","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0013","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamainternmed.2019.7495","article-title":"Empirical anti-MRSA vs standard antibiotic therapy and risk of 30-day mortality in patients hospitalized for pneumonia","volume":"180","author":"Jones","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0014","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/jamainternmed.2019.7251","article-title":"Overuse of broad-spectrum antibiotics for pneumonia","volume":"180","author":"Klompas","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0015","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2147\/IDR.S165669","article-title":"Validation of the prediction rules identifying drug-resistant pathogens in community-onset pneumonia","volume":"11","author":"Kobayashi","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijid.2022.09.015_bib0016","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1086\/526355","article-title":"Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes\u2013proceedings of the HCAP summit","volume":"46","author":"Kollef","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.015_bib0017","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1378\/chest.09-0087","article-title":"Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock","volume":"136","author":"Kumar","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.ijid.2022.09.015_bib0018","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1093\/cid\/ciaa1902","article-title":"Risk of acute kidney injury and clostridioides difficile infection with piperacillin\/tazobactam, cefepime, and meropenem with or without vancomycin","volume":"73","author":"Lee","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.015_bib0019","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","article-title":"Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis","volume":"46","author":"Luther","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0020","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.015_bib0021","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.015_bib0022","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.200411-1444OC","article-title":"Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome","volume":"172","author":"Men\u00e9ndez","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0023","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/resp.12651","article-title":"Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia","volume":"21","author":"Metersky","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.ijid.2022.09.015_bib0024","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0025","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/resp.13232","article-title":"Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: impact of beta-lactam plus macrolide combination therapy","volume":"23","author":"Okumura","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.ijid.2022.09.015_bib0026","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.chest.2020.07.089","article-title":"International perspective on the new 2019 American Thoracic Society\/Infectious Diseases Society of America community-acquired pneumonia guideline: a critical appraisal by a global expert panel","volume":"158","author":"Pletz","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.ijid.2022.09.015_bib0027","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1513\/AnnalsATS.201407-305OC","article-title":"Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia","volume":"12","author":"Prina","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ijid.2022.09.015_bib0028","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1378\/chest.08-1357","article-title":"Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital","volume":"135","author":"Shindo","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.ijid.2022.09.015_bib0029","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201301-0079OC","article-title":"Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia","volume":"188","author":"Shindo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0030","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(15)00151-6","article-title":"Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study","volume":"15","author":"Shindo","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.015_bib0031","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/resp.13135","article-title":"Regional differences in antibiotic-resistant pathogens in patients with pneumonia: implications for clinicians","volume":"22","author":"Shindo","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.ijid.2022.09.015_bib0032","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/cir813","article-title":"Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department","volume":"54","author":"Shorr","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.09.015_bib0033","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba0501","article-title":"The microbiota in pneumonia: from protection to predisposition","volume":"13","author":"Thibeault","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0034","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41572-021-00259-0","article-title":"Pneumonia","volume":"7","author":"Torres","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ijid.2022.09.015_bib0035","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00134-013-2828-9","article-title":"Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients","volume":"39","author":"Tumbarello","year":"2013","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijid.2022.09.015_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2016.03.008","article-title":"Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis","volume":"48","author":"Vardakas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2022.09.015_bib0037","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jhin.2011.05.007","article-title":"Identifying new risk factors for Pseudomonas aeruginosa pneumonia in intensive care units: experience of the French national surveillance, rea-RAISIN","volume":"79","author":"Venier","year":"2011","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijid.2022.09.015_bib0038","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1128\/AAC.03071-15","article-title":"Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score","volume":"60","author":"Webb","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.09.015_bib0039","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00057-2019","article-title":"Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study","volume":"54","author":"Webb","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2022.09.015_bib0040","unstructured":"World Health Organization. Antimicrobial resistance. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance, 2021 (accessed 13 June 2022)."},{"key":"10.1016\/j.ijid.2022.09.015_bib0041","unstructured":"World Health Organization. The top 10 causes of death. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death, 2020 (accessed 13 June 2022)."},{"key":"10.1016\/j.ijid.2022.09.015_bib0042","doi-asserted-by":"crossref","first-page":"j2471","DOI":"10.1136\/bmj.j2471","article-title":"Advances in the causes and management of community acquired pneumonia in adults","volume":"358","author":"Wunderink","year":"2017","journal-title":"BMJ"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222005161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222005161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:10:19Z","timestamp":1761120619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222005161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":42,"alternative-id":["S1201971222005161"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.09.015","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended-spectrum antibiotics for community-acquired pneumonia with a low risk for drug-resistant pathogens","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}